![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00733863 |
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.
Condition | Intervention | Phase |
---|---|---|
Alzheimer Disease |
Biological: Placebo Biological: CAD106 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 |
Enrollment: | 27 |
Study Start Date: | July 2008 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Biological: CAD106 |
2: Placebo Comparator | Biological: Placebo |
Ages Eligible for Study: | 40 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
Centre Hospitalier Universitaire Pellegrin | |
Bordeaux, France | |
Sweden | |
Karolinska Universitetssjukhuset Huddinge | |
Stockholm, Sweden | |
Switzerland | |
NeuroPsychologieZentrum | |
Basel, Switzerland | |
United Kingdom | |
Moorgreen Hospital | |
Southampton, United Kingdom |
Principal Investigator: | Novartis Pharmaceuticals | Novartis |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CCAD106A2201 |
Study First Received: | August 8, 2008 |
Last Updated: | March 31, 2009 |
ClinicalTrials.gov Identifier: | NCT00733863 History of Changes |
Health Authority: | Switzerland: Swissmedic |
Active immunization Alzheimer disease Antibody |
Central Nervous System Diseases Neurodegenerative diseases Vaccine |
Antibodies Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Brain Diseases |
Dementia Neurodegenerative Diseases Cognition Disorders Coronary Artery Disease Immunoglobulins Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Nervous System Diseases Alzheimer Disease Central Nervous System Diseases |
Neurodegenerative Diseases Tauopathies Brain Diseases Dementia |